Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great entry price!
Elixinol Global Ltd. (ELLXF)
2.68 ? -0.138 (-4.90%)
Volume: 230,755 @07/23/19 3:58:41 PM EDT
Bid Ask Day's Range
2.65 2.72 2.64 - 2.845
ELLXF Detailed Quote
Elixinol continues to build Leadership team:
insert-text-here
Elixinol Is A Uniquely Positioned Legitimate Threat In The Cannabis And CBD Space
https://seekingalpha.com/article/4276302-elixinol-uniquely-positioned-legitimate-threat-cannabis-cbd-space?dr=1&fbclid=IwAR0qoe1qoPWVbdvthHvx88d5-ngAi2Y0yfB0rqZzq2VYbmYVhVqpna9_FD0
Elixinol acquires global IP rights for microencapsulation
technology - provides benefits to many sectors including food,
beverage and nutraceuticals
insert-text-here
Welcome aboard. Good company. This also trades on the ASX - you can follow delayed prices here: insert-text-here
Thousands Of Comments Urge FDA To Allow CBD In Foods And Supplements
insert-text-here
Yes the tide is turning!
Looks like it did spike to $4.18 on ASX when news came out and then closed down a nickel, at $3.95.
Huge news, Pan O War. Should soar tonight on ASX.
Nunyara Manufacturing License Granted:
insert-text-here
ELLXF: Elixinol restructures board ahead of international push
https://www.businessnewsaus.com.au/articles/elixinol-restructures-board-ahead-of-international-push.html
Written on the 16 July 2019 by Paris Faint
There's been a reshuffle at the top of Australia's largest cannabis company.
Elixinol Global (ASX: EXL) has announced changes to both its executive team and board ahead of a crucial period of expansion.
Stratos Karousos has taken the reigns as CEO, replacing co-founder Paul Benhaim (pictured) who will transition to the role of chief innovation officer.
Both Karousos and Benhaim will sit on the board as Elixinol focuses on expanding its Sydney-based global executive office and increasing its regional support.
Non-executive chairman Andrew Duff says the leadership changes and expansion is timely, given the company's fast-growing scale and status as the country's largest cannabis player.
"These group structure changes will better enable Elixinol Global to capitalise on the significant industry opportunity, and reflect Elixinol Global's continued and exciting growth," says Duff.
"The company is now of a scale that coordinated global resources are necessary to leverage insights and create efficiencies."
Elixinol Global was formed in January 2018 when Colorado-based Elixinol LLC joined forces with Hemp Foods Australia to form a new worldwide brand and launch an IPO.
Under the company structure, Hemp Foods Australia is the manufacturer and distributor of hemp food products and skin care, while Elixinol LLC is the bulk and retail provider of hemp-based cannabidiol (CBD) dietary supplements and topical products.
Although Benhaim is no longer at the helm as CEO, he is excited to move back into a hands-on role.
"I'm delighted the company is moving to its next phase of growth. My new role frees me up to focus on my passion for innovation and product development and the company will benefit from Stratos' commercial and business process focus," he says.
Following Elixinol's recent successful $50 million capital raising, Karousos says the company will continue to tackle the hemp-derived CBD market, particularly in the United States.
"Elixinol Global currently has a broad business, both geographically and by product line," he says.
"The plan is to critically review where we want to focus our efforts in the near-term and prioritise areas with the greatest potential.
"We believe the opportunity in the global CBD market, in particular the US, is substantial."
At the time of writing (10:24am AEST), EXL shares are trading at $4.10.
Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.
FDA Comment Period ends tonight at midnight: insert-text-here
Not today. Hopefully soon!
Elixinol announces Leadership and Group Structure Update
https://www.elixinolglobal.com/site/PDF/2519_0/LeadershipandGroupStructureupdate
U.S. CBD Sales to Grow an Average of 107% Annually Through 2023: https://www.fool.com/investing/2019/07/14/us-cbd-sales-to-grow-an-average-of-107-annually-th.aspx
FDA Says It Is Speeding Up The CBD Regulation Process
insert-text-here
FDA to provide update on CBD review by late summer or fall:
insert-text-here
Looking like the $3's will hold again today (looking at ASX). We are def in a new up-trend!
ELLXF Quarterly Report due end of July.
Looking really good!
I think we could break + hold the $3s today!
Level 2s looking great!
Up 7.5% on ASX last night.
Decent day! Starting to move in the right direction again!
Cannabis company Elixinol Global storms higher on Germany deal
From Motley Fool Australian edition
https://au.finance.yahoo.com/news/cannabis-company-elixinol-global-storms-003706942.html
Patience is the key here in this sector by end of year when all the laws and regulations are final that’s when we’ll see real money. Don’t get me wrong you can make money all the way but Big money by end of year beginning of next IMO GLTA
Very, very great article on the company and on Paul Benhaim. I feel good about having this company in my portfolio. Thank you for posting !
People don't like to click on a "blind link". If you would provide just a line or two about the subject matter you will find that there is much more interest.
An interesting listen: insert-text-here
I love this in regards to dosing:
"They also cite research by Greenwich Biosciences that alleges that CBD is potentially toxic to the liver – a finding that has been disputed by the CED Foundation, who note that the mice in the study were given the human equivalent of 42,050 milligrams of CBD, which they called “an unreasonable amount.”
“In the days where many people are taking 10mg pills of CBD per day, the amounts of CBD that were force-fed to these animals in this study, if translated to humans, would be 4,305mg, 12,915mg, and 43,050mg over 10 days, or 17,220mg, 51,660mg, and 172,200mg in one-shot doses.),” the foundation wrote in a June 20 rebuttal to a Forbes article by Mike Adams. “For reference, these days, most dispensaries sell CBD in doses of 10mg, 20mg, up to 2-300mg.)”
insert-text-here
USDA Sets Target Deadline To Release Hemp Regulations: insert-text-here
FDA extends Public comment period to July 16th: insert-text-here
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1174
|
Created
|
09/18/18
|
Type
|
Free
|
Moderators |
50 Pitt Street,
Level 6
Sydney, NSW 2000
Australia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |